Compare ARK Genomic Revolution ETF (ARKG) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Gold Fields Limited — how do they compare? ARK Genomic Revolution ETF trades at $40.8, while Gold Fields Limited trades at $33.2 (market cap $30.43B). The key difference: Gold Fields Limited pays a 6.79% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Gold Fields Limited nearer its low. Which is the better fit depends on your goals.
| ARKG | GFI | |
|---|---|---|
Sector | Sector/Thematic | Basic Materials |
52-Week High | $43.57 | $61.52 |
52-Week Low | $23.09 | $23.95 |
Market Cap | — | $30.43B |
Enterprise Value | — | $31.87B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Gold Fields (GFI) trades at $34.14, up 0.29% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong profitability with a 40.76% net income margin and 52.33% ROE, supported by revenue growth from $5.2B in 2024 to a projected $8.8B in 2025. Recent news highlights operational challenges amid gold price volatility, with Q1 2025 production up 15% but costs rising 13% due to inflation (Seeking Alpha, 2026-06-29).
The outlook is mixed: analyst consensus is a Buy with a $53.13 price target, implying 56% upside, but technical weakness and earnings misses in Q2 and Q4 2025 pose near-term risks. Long-term value hinges on cost control and gold price stability, with debt-to-asset ratio improvements from 25.01% in 2024 to 18.27% in 2025 signaling stronger balance sheet health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
